Chronic myeloid leukemia with an e13a3 BCR‐ABL fusion: Benign course responsive to imatinib with an RT‐PCR advisory
- 23 January 2004
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 75 (2), 92-95
- https://doi.org/10.1002/ajh.10456
Abstract
A case of a patient with chronic myeloid leukemia whose cells expressed an e13a3 (b2a3) variant BCR‐ABL p210 mRNA is presented. The variant splice was detected by a qualitative reverse transcriptase polymerase chain reaction using primers complementary to BCR exon 13 (b2) and ABL exon 3 (a3). The patient responded well to imatinib and achieved a complete cytogenetic response. Am. J. Hematol. 75:92–95, 2004.This publication has 14 references indexed in Scilit:
- A Rare, In-Frame BCR-ABL Fusion (e13a3) in a Patient with an Aggressive Chronic Myeloid LeukaemiaActa Haematologica, 2002
- CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfallBlood, 2002
- Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571Online Journal of Public Health Informatics, 2002
- Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loopProceedings of the National Academy of Sciences of the United States of America, 2002
- The e19a2 BCR/ABL fusion transcript with additional chromosomal aberrations on a new case of chronic myeloid leukemia (CML) of mild typeLeukemia, 2001
- Quality assurance in RT-PCR-based BCR/ABL diagnostics – results of an interlaboratory test and a standardization approachLeukemia, 2000
- Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for LeukemogenesisThe Journal of Experimental Medicine, 1999
- 2 BCR-ABL gene variantsBailliere's Clinical Haematology, 1997
- Characterization of mutations in phenotypic variants of hypoxanthine phosphoribosyltransferase deficiencyHuman Molecular Genetics, 1992
- PERSISTENCE OF bcr-abl GENE EXPRESSION FOLLOWING BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASETransplantation, 1991